Faculty Collaboration Database

New agents, new rashes: an update on skin complications from cancer chemotherapy. Curr Oncol Rep 2006 Jul;8(4):269-74

Date

01/27/2007

Pubmed ID

17254526

DOI

10.1007/s11912-006-0032-6

Scopus ID

2-s2.0-33745647249 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

Several new drugs have emerged as effective antineoplastic agents in the past 5 years. Many of these drugs cause rashes. For example, rash is one of the two most frequent adverse events that occur in cancer patients prescribed epidermal growth factor receptor inhibitors. This review discusses rash in the context of epidermal growth factor receptor inhibitors and in the context of a few other recently approved cancer drugs. It also embarks on a brief discussion of issues that investigators must face when designing clinical trials aimed at rash palliation.

Author List

Patiyil S, Chan SN, Jatoi A

MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Drug Eruptions
Humans
Neoplasms
Skin Diseases